Tranzyme plummets on Phase IIb miss for TZP-102
Shares of Tranzyme Inc. (NASDAQ:TZYM) plummeted $3.02 (76%) to $0.95 on Thursday after the company reported that once-daily 10 and 20 mg oral TZP-102 each missed the primary endpoint in a Phase IIb trial to treat diabetic gastroparesis. Specifically, low- and high-dose TZP-102 did not reduce Gastroparesis Symptom Daily Diary (GSDD) composite score from baseline during the last two weeks of the 12-week treatment period vs. placebo (1.7 and 1.43 points, respectively, vs. 1.46 points, p-values not disclosed). The double-blind, international Phase IIb trial enrolled 201 patients with Type I or II diabetes and a confirmed diagnosis of gastroparesis. Top-line data from the Phase IIb DIGEST trial evaluating thrice-daily 10 mg TZP-102 given before meals to treat diabetic gastroparesis are expected in 1H13. TZP-102 is an oral ghrelin agonist. ...